BTAI BioXcel Therapeutics Inc

Price (delayed)

$1.26

Market cap

$38.91M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.52

Enterprise value

$122.01M

?
Relative Growth: Rel. Growth: 40
Relative Strength: Rel. Strength: 7
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 6

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically ...

Highlights
BTAI's EPS has surged by 65% year-on-year and by 21% since the previous quarter
BTAI's debt is down by 8% since the previous quarter and by 5% year-on-year
BTAI's revenue has dropped by 63% year-on-year but it is up by 6% since the previous quarter
BioXcel Therapeutics's net income has shrunk by 88% YoY and by 8% QoQ
BTAI's quick ratio has dropped by 74% year-on-year and by 41% since the previous quarter

Key stats

What are the main financial stats of BTAI

BTAI stock price

How has the BioXcel Therapeutics stock price performed over time
Intraday
8.62%
1 week
0%
1 month
0%
1 year
-17.65%
YTD
-21.25%
QTD
-5.97%

Financial performance

How have BioXcel Therapeutics's revenue and profit performed over time
Revenue
$680,000
Gross profit
$247,000
Operating income
-$50.59M
Net income
-$75.33M
Gross margin
36.3%
Net margin
-11,078.5%
BTAI's operating margin has shrunk by 159% YoY but it is up by 5% QoQ
BioXcel Therapeutics's net income has shrunk by 88% YoY and by 8% QoQ
BTAI's revenue has dropped by 63% year-on-year but it is up by 6% since the previous quarter
BTAI's gross margin has dropped by 51% since the previous quarter

Price vs fundamentals

How does BTAI's price correlate with its fundamentals

Growth

What is BioXcel Therapeutics's growth rate over time

Valuation

What is BioXcel Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
43.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
179.43
BTAI's EPS has surged by 65% year-on-year and by 21% since the previous quarter
The equity has declined by 17% year-on-year and by 11% since the previous quarter
BTAI's revenue has dropped by 63% year-on-year but it is up by 6% since the previous quarter
The price to sales (P/S) is 14% higher than the last 4 quarters average of 35.4

Efficiency

How efficient is BioXcel Therapeutics business performance
BioXcel Therapeutics's ROIC has plunged by 180% YoY and by 19% from the previous quarter
BioXcel Therapeutics's return on assets has shrunk by 140% YoY and by 11% QoQ
BTAI's return on sales is down by 3.7% since the previous quarter

Dividends

What is BTAI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BTAI.

Financial health

How did BioXcel Therapeutics financials performed over time
The total assets is 76% less than the total liabilities
BTAI's quick ratio has dropped by 74% year-on-year and by 41% since the previous quarter
BTAI's current ratio has plunged by 58% YoY and by 25% from the previous quarter
BTAI's debt is 195% greater than its equity
BioXcel Therapeutics's debt to equity has increased by 19% YoY and by 17% from the previous quarter
The equity has declined by 17% year-on-year and by 11% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.